[Hematological disorders and hypereosinophilias]

Area of Science:

• Hematology
• Oncology
• Immunology

Context:

• Hematological disorders represent the third leading cause of hypereosinophilia, following allergic and parasitic conditions.
• Recent advancements in cytogenetics, molecular biology, and immunology have refined the classification of hypereosinophilic disorders.
• Distinguishing between clonal, reactive, and idiopathic eosinophilias is crucial for accurate diagnosis and treatment.

Purpose:

• To review the classification and diagnostic work-up of hypereosinophilic disorders, particularly those of hematological origin.
• To highlight the role of molecular and genetic abnormalities in diagnosing chronic eosinophilic leukemia.
• To discuss current and emerging therapeutic strategies for hypereosinophilic syndromes and related disorders.

Summary:

• Hematological disorders causing hypereosinophilia are categorized as clonal, reactive, or idiopathic.
• Reactive eosinophilias are often linked to lymphoma or abnormal T-cell populations, while clonal eosinophilia involves myeloid malignancies or eosinophilic lineage myeloproliferative disorders.
• Chronic eosinophilic leukemia can feature gene rearrangements (PDGFRA, PDGFRB, FGFR1) or other clonal abnormalities. Idiopathic hypereosinophilic syndrome is diagnosed with unexplained eosinophilia and organ damage.
• Diagnostic work-up aims to detect abnormal T-cell populations or clonal hematopoiesis.
• Imatinib mesylate is effective for PDGFR-associated chronic eosinophilic leukemias; corticosteroids are standard for others.

Impact:

• Improved diagnostic accuracy for hypereosinophilic syndromes through advanced molecular and immunological techniques.
• Identification of specific genetic targets (e.g., PDGFR, FGFR1) leading to more effective, targeted therapies like imatinib mesylate.
• Potential for novel treatments, including anti-IL-5 antibodies, and further gene discovery to address currently untreatable clonal eosinophilias.